PuSH - Publication Server of Helmholtz Zentrum München: Recent achievements and future directions of anti-obesity medications.

Navigation

Home

Deutsch

Research

Advanced Search

Browse by ...

... Journal

... Publication Type

... Research Data

... Publication Year

Publication overview

Support & Contact

Contact persons

Help

Data protection

Grandl, G. ; Novikoff, A. ; Liu, X. ; Müller, T.D.

Recent achievements and future directions of anti-obesity medications.

Lancet Reg. Health-Eur. 47:101100 (2024)

Publ. Version/Full Text

DOI

PMC

	Free journal

Abstract
Metrics
Extra information

Pharmacological management of obesity long suffered from a reputation of a 'Mission Impossible,' with inefficient weight loss and/or unacceptable tolerability. However, the tide has turned with recent progress in biochemical engineering and the development of long-acting agonists at the receptor for glucagon-like peptide-1 (GLP-1), and with unimolecular peptides that simultaneously possess activity at the receptors for GLP-1, the glucose-dependent insulinotropic polypeptide (GIP) and glucagon. Some of these novel therapeutics not only improve body weight and glycemic control in individuals with obesity and type 2 diabetes with hitherto unmet efficacy and tolerable safety, but also exhibit potential therapeutic value in diverse areas such as neurodegenerative diseases, fatty liver disease, dyslipidemia, atherosclerosis, and cardiovascular diseases. In this review, we highlight recent advances in incretin-based therapies and discuss their pharmacological potential within and beyond the treatment of obesity and diabetes, as well as their limitations in use, side effects, and underlying molecular mechanisms.

Altmetric

Additional Metrics?

[➜Log in]

Edit extra informations Login

Publication type Article: Journal article

Document type Review

Corresponding Author

Keywords Anti-obesity Medication (aom) ; Diabetes ; Gip ; Glp-1 ; Obesity; Glucagon-like Peptide-1; Dependent Insulinotropic Polypeptide; Once-weekly Semaglutide; Glp-1 Receptor Agonist; Inhibits Bone-resorption; Double-blind; Cardiovascular Outcomes; Parallel-group; Body-weight; Open-label

ISSN (print) / ISBN 2666-7762

e-ISSN 2666-7762

Journal The Lancet Regional Health - Europe

Quellenangaben Volume: 47, Article Number: 101100

Publisher Elsevier

Publishing Place Radarweg 29, 1043 Nx Amsterdam, Netherlands

Non-patent literature Publications

Reviewing status Peer reviewed

Institute(s) Institute of Diabetes and Obesity (IDO)

Grants German Center for Diabetes Research (DZD e.V.)
German Research Foundation
Neither the European Union
European Union